High response rates with bevacizumab, docetaxel, and carboplatin in patients with HER2-negative advanced breast cancer: An experience of 22 case reports.

e11538 Background: Monoclonal antibodies, such as bevacizumab, stop tumor growth and block the ability of tumor cells to grow and spread. Others drugs find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with docetaxel and carboplatin may kill more tumor cells. The aim of this study was to determine the clinical response rate in women with metastatic breast cancer and Her2 negative treated with bevacizumab, docetaxel, and carboplatin. Methods: Twenty two patients Her2 negative with diagnostic of metastatic breast cancer were included and received bevacizumab (15mg/kg), docetaxel (75mg/m2), and carboplatin (AUC 5) on day 1 and were repeated every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity. Results: Overall clinical response rate w...